Opendata, web and dolomites

MS-INFINITE SIGNED

MASS SPECTROMETRY WITHOUT LIMITS: Pioneer MS equipment and Automated Sample Preparation unit to boost New Therapies Development

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MS-INFINITE project word cloud

Explore the words cloud of the MS-INFINITE project. It provides you a very rough idea of what is the project "MS-INFINITE" about.

infinite    standard    pharmaceutical    selling    alzheimer    medicine    modern    revenue    solution    2020    innovation    reproducibly    tof    generate    combined    time    prepare    trials    small    generating    ineffective    tool    despite    mass    pioneering    primary    too    experts    1bn    cures    spectrometer    comprising    instrumentation    saving    enter    detection    times    specialists    incompatible    proteins    biotechnology    regardless    2022    ms    nanoparticles    launch    material    1st    macromolecules    spectrometers    kda    analytical    molecular    therapies    market    detectors    meet    quantitatively    nanomedicine    model    determined    maldi    conventional    masses    drugs    believe    demands    landscapes    quantitative    cancer    business    commercialise    calibration    preparation    offers    industry    patent    rely    quantification    clinical    cumulative    concentration    profit    size    failing    multicomponent    molecules    first    arthritis    analytes    jobs    11m    efficiency    weight    plan    company    18    spectrometry    analyte    roi    constituents    asp    viruses    submitted    estimating    life    2015    automated    heavy    revenues    100    cryodetector   

Project "MS-INFINITE" data sheet

The following table provides information about the project.

Coordinator
METEXPERT SARL 

Organization address
address: RUE DU CHATEAU 10
city: NEUCHATEL
postcode: 2000
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.metromol.ch/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    METEXPERT SARL CH (NEUCHATEL) coordinator 50˙000.00

Map

 Project objective

Modern medicine is evolving. Traditional drugs are small molecules with masses under 1 kDa. Emerging therapies increasingly rely on macromolecules 100 times this size: proteins, nanoparticles, viruses etc. Mass spectrometry is the primary tool for quantitative measurement in the pharmaceutical industry, generating revenues of €1.1Bn in 2015, but is failing to meet new demands. Conventional MS detectors become ineffective at 50 kDa making them incompatible with the emerging landscapes of biotechnology and nanomedicine. With a combined 70 years’ experience in analytical instrumentation, we plan to commercialise MS-INFINITE, our solution for large analyte mass quantification. MS-INFINITE is a multicomponent system, comprising a cryodetector MALDI-TOF mass spectrometer allowing 100% detection efficiency, regardless of molecular mass. MS-INFINITE also offers a pioneering calibration method, allowing concentration of specific constituents of large analytes to be quantitatively determined by MS for the first time (patent submitted). Through a unique business model, MS-INFINITE will generate revenue by selling an Automated Sample Preparation (ASP) unit to end-users, allowing non-specialists to reproducibly prepare clinical and pharmaceutical material for measurement. The market launch of MS-INFINITE’s ASP unit (2022) will bring the 1st revenues into our company, generating 18 new jobs, a cumulative profit of €11M, and a 5-years ROI of 5. Despite this, we believe our impact will be far more significant than company growth: MS-INFINITE has the potential to become the standard tool for quantification of analytes too heavy for existing mass spectrometers. With experts estimating that over 100 high molecular weight therapies will enter phase II or III clinical trials in 2020, our innovation will facilitate the development of pioneering advances in biotechnology and nanomedicine, allowing research to advance towards life-saving cures for cancer, Alzheimer’s and arthritis.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MS-INFINITE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MS-INFINITE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More  

ALICE (2019)

Armored Liftable anti-Intrusion Control Equipment

Read More